Compare Ishares Msci Thailand Etf (THD) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Thailand Etf vs Viatris Inc — how do they compare? Ishares Msci Thailand Etf trades at $73.52, while Viatris Inc trades at $17.37 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while Ishares Msci Thailand Etf pays none. Which is the better fit depends on your goals.
| THD | VTRS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $75.05 | $17.39 |
52-Week Low | $55.83 | $8.74 |
Market Cap | — | $19.79B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
THD trades at $73.02, up 0.21% on the day, with a bullish technical outlook supported by moving averages and an upcoming dividend of $1.71 scheduled for June 2026. Recent news highlights its strong performance, with nearly 38% total returns over the past year, driven by exposure to AI hardware plays like Delta Electronics. The stock's momentum is reinforced by positive sentiment from financial media, though key financial ratios remain undisclosed in the provided data.
Outlook is cautiously optimistic due to technical strength and AI-driven growth potential, but risks include vulnerability to profit-taking and macroeconomic factors. Investors should monitor earnings reports for fundamental validation, as current data lacks detailed financial metrics. The stock faces competition and regional economic shifts, requiring careful assessment of future guidance.
Viatris (VTRS) trades at $17.10, down 1.1% today but maintains a bullish technical outlook with strong moving average signals. The company shows mixed fundamentals with recent earnings beats but negative profitability metrics, while analyst consensus leans toward Hold with a $20 price target. Recent positive developments include FDA acceptance of new drug applications and pipeline progress in biosimilars.
Viatris presents a value opportunity with reasonable P/S and P/B ratios, but faces challenges with negative margins and high debt. The stock's upside potential depends on successful pipeline execution and debt reduction, while risks include competitive pressures and execution missteps in a challenging pharmaceutical market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ishares Msci Thailand Etf
THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
